keyword
https://read.qxmd.com/read/38657278/younger-unrelated-donors-may-be-preferable-over-hla-match-in-the-ptcy-era-a-study-from-the-alwp-of-the-ebmt
#1
JOURNAL ARTICLE
Jaime Sanz, Myriam Labopin, Goda Choi, Alexander Kulagin, Jacopo Peccatori, Jan Vydra, Peter Pal Remenyi, Jurjen Versluis, Montserrat Rovira, Didier Blaise, Helene Labussiere-Wallet, Juan Montoro, Simona Sica, Ellen Meijer, Maija Itälä-Remes, Nicolaas Schaap, Claude-Eric Bulabois, Simona Piemontese, Mohamad Mohty, Fabio Ciceri
There is a paucity of information on how to select the most appropriate unrelated donor (UD) in hematopoietic stem cell transplant (HSCT) using post-transplant cyclophosphamide (PTCy). We retrospectively analyzed the characteristics of 10/10 matched unrelated donors (MUD) and 9/10 mismatched unrelated donors (MMUD) that may affect transplant outcomes in patients with acute myeloid leukemia (AML) in first or second complete remission (CR1 or CR2). The primary endpoint was leukemia-free survival (LFS). Overall, 1011 patients were included with a median age of 54 years (range, 18-77)...
March 29, 2024: Blood
https://read.qxmd.com/read/38657272/current-and-upcoming-treatment-approaches-to-uncommon-subtypes-of-ptcl-eatl-meitl-sptcl-hstcl
#2
JOURNAL ARTICLE
Enrica Marchi, Jeffrey W Craig, Matko Kalac
Rare subtypes of peripheral T-cell lymphoma (PTCL) including enteropathy-associated T-cell lymphoma (EATL), monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), subcutaneous panniculitis-like T-cell lymphoma (SPTCL) and hepatosplenic T-cell lymphoma (HSTCL) are underrepresented in most registry and clinical studies. Most of the literature is obtained from small case series, single-institution retrospective studies and subgroup analyses of the largest studies with few recent and ongoing exceptions...
April 24, 2024: Blood
https://read.qxmd.com/read/38657263/how-i-treat-philadelphia-chromosome-like-acute-lymphoblastic-leukemia-in-children-adolescents-and-young-adults
#3
JOURNAL ARTICLE
Thai Hoa Tran, Sarah K Tasian
Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) represents a high-risk B-lineage ALL subtype characterized by adverse clinical features and poor relapse-free survival despite risk-adapted multi-agent chemotherapy regimens. The advent of next-generation sequencing has unraveled the diversity of kinase-activating genetic drivers in Ph-like ALL that are potentially amenable to 'personalized' molecularly-targeted therapies. Based upon robust preclinical data and promising case series of clinical activity of tyrosine kinase inhibitor (TKI)-based treatment in adults and children with relevant genetic Ph-like ALL subtypes, several clinical trials have investigated the efficacy of JAK- or ABL-directed TKIs in CRLF2/JAK pathway-mutant or ABL-class Ph-like ALL, respectively...
April 24, 2024: Blood
https://read.qxmd.com/read/38657244/sequential-cd7-car-t-cell-therapy-and-allogeneic-hsct-without-gvhd-prophylaxis
#4
JOURNAL ARTICLE
Yongxian Hu, Mingming Zhang, Tingting Yang, Zhuomao Mo, Guoqing Wei, Ruirui Jing, Houli Zhao, Rongrong Chen, Cheng Zu, Tianning Gu, Pingnan Xiao, Ruimin Hong, Jingjing Feng, Shan Fu, Delin Kong, Huijun Xu, Jiazhen Cui, Simao Huang, Bin Liang, Xiaolin Yuan, Qu Cui, Hongshan Guo, Yunxian Yu, Youqin Feng, Chunxiang Jin, Jiangtao Ren, Alex H Chang, Dongrui Wang, He Huang
BACKGROUND: Patients with relapsed or refractory hematologic cancers have a poor prognosis. Chimeric antigen receptor (CAR) T-cell therapy as a bridge to allogeneic hematopoietic stem-cell transplantation (HSCT) has the potential for long-term tumor elimination. However, pre-HSCT myeloablation and graft-versus-host disease (GVHD) prophylaxis agents have toxic effects and could eradicate residual CAR T cells and compromise antitumor effects. Whether the integration of CAR T-cell therapy and allogeneic HSCT can preserve CAR T-cell function and improve tumor control is unclear...
April 25, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38657242/efficacy-of-car-t-cell-therapy-is-not-impaired-by-previous-bispecific-antibody-treatment-in-large-b-cell-lymphoma
#5
JOURNAL ARTICLE
Gilles Crochet, Gloria Iacoboni, Audrey Couturier, Emmanuel Bachy, Josu Iraola-Truchuelo, Thomas Gastinne, Guillaume Cartron, Tom Fradon, Bastien Lesne, Mi Kwon, Romain Gounot, Nuria Martínez-Cibrian, Cristina Castilla-Llorente, Pau Abrisqueta, Manuel Guerreiro, Clémentine Sarkozy, José María Aspa-Cilleruelo, Vincent Camus, Stéphanie Guidez, Adrien Chauchet, Eric Deconinck, Krimo Bouabdallah, Francesc Bosch, Pere Barba, Franck Morschhauser, Houot Roch
In this retrospective study, CAR T-cells remained effective in relapsed/refractory LBCL patients after prior exposure to bispecific antibodies (BsAbs) targeting different antigens. These results are relevant to clinical practice, particularly given the increasing use of BsAbs in earlier treatment lines.
April 24, 2024: Blood
https://read.qxmd.com/read/38657230/real-world-registry-on-the-pharmacotherapy-of-multiple-myeloma-and-associated-renal-and-pulmonary-impairments-in-the-greater-gulf-region-protocol-for-a-retrospective-real-world-data-study
#6
JOURNAL ARTICLE
Abdulnaser Nourallah, Abdulrahman Alshehri, Ayman Alhejazi, Binyam Usman, Ghada ElGohary, Hafiz Malhan, Ibraheem Motabi, Khalil Al Farsi, Mohammed Alshuaibi, Mustaqeem Siddiqui, Rasha Ghonema, Ruba Yasin Taha, Tarek Abouzeid, Wesam Ahmed, Mohanad Diab, Ahmad Alhuraiji, Magdy Rabea, Mohamed Zahir Chouikrat
BACKGROUND: Multiple myeloma (MM) is the second-most common cancer among hematological malignancies. Patients with active disease may experience several comorbidities, including renal insufficiency and asthma, which may lead to treatment failure. The treatment of relapsed or refractory MM (RRMM) has been associated with multiple factors, causing a decline in progression-free survival as well as overall survival with subsequent lines of therapy. Data about the characteristics of this group of patients in the Greater Gulf region are lacking...
April 24, 2024: JMIR Research Protocols
https://read.qxmd.com/read/38657201/correlation-of-immune-fitness-with-response-to-teclistamab-in-relapsed-refractory-multiple-myeloma-in-majestec-1
#7
JOURNAL ARTICLE
Diana Cortes-Selva, Tatiana Perova, Sheri Skerget, Deeksha Vishwamitra, Sarah Stein, Rengasamy Boominathan, On Say Lau, Karl Nielsen, Cuc Davis, Jaymala H Patel, Arnob Banerjee, Tara Stephenson, Clarissa Uhlar, Rachel Kobos, Jenna D Goldberg, Lixia Pei, Danielle Trancucci, Suzette Girgis, Shun Xin Wang Lin, Liviawati S Wu, Philippe Moreau, Saad Z Usmani, Nizar J Bahlis, Niels W C J van de Donk, Raluca Verona
Teclistamab, an off-the-shelf B-cell maturation antigen (BCMA) × CD3 bispecific antibody that mediates T-cell activation and subsequent lysis of BCMA-expressing myeloma cells, is approved for the treatment of patients with relapsed/refractory multiple myeloma (RRMM). As a T-cell redirection therapy, clinical outcomes with teclistamab may be influenced by patient immune fitness and tumor antigen expression. We correlated tumor characteristics and baseline immune profiles with clinical response and disease burden in patients with RRMM from the pivotal phase 1/2 MajesTEC-1 study, focusing on patients treated with 1...
April 24, 2024: Blood
https://read.qxmd.com/read/38657197/gasdermin-d-drives-focal-crystalline-thrombotic-microangiopathy-by-accelerating-immunothrombosis-and-necroinflammation
#8
JOURNAL ARTICLE
Kanako Watanabe-Kusunoki, Chenyu Li, Tâmisa Seeko Bandeira Honda, Danyang Zhao, Yoshihiro Kusunoki, John Ku, Hao Long, Martin Klaus, Chao Han, Attila Braun, Elmina Mammadova-Bach, Andreas Linkermann, Kristof Van Avondt, Mathis Richter, Oliver Soehnlein, Monika I Linder, Christoph Klein, Stefanie Steiger, Hans-Joachim Anders
Thrombotic microangiopathy (TMA) is characterized by immunothrombosis and life-threatening organ failure, but the precise underlying mechanism driving its pathogenesis remains elusive. In this study, we hypothesized that gasdermin D (GSDMD), a pore-forming protein serving as the final downstream effector of pyroptosis/interleukin (IL)-1pathway, contributes to TMA and its consequences by amplifying neutrophil maturation and subsequent necrosis. Using a murine model of focal crystalline TMA, we found that Gsdmd-deficiency ameliorated immunothrombosis, acute tissue injury and failure...
April 24, 2024: Blood
https://read.qxmd.com/read/38657191/the-atf4-rps19bp1-axis-modulates-ribosome-biogenesis-to-promote-erythropoiesis
#9
JOURNAL ARTICLE
Zhaofeng Zheng, Shangda Yang, Fanglin Gou, Chao Tang, Zhaoru Zhang, Quan Gu, Guohuan Sun, Penglei Jiang, Nini Wang, Xiangnan Zhao, Junnan Kang, Yifei Wang, Yicheng He, Meng Yang, Ting Lu, Shihong Lu, Pengxu Qian, Ping Zhu, Hui Cheng, Tao Cheng
Hematopoietic differentiation is controlled by intrinsic regulators and the extrinsic hematopoietic niche. Activating transcription factor 4 (ATF4) plays a crucial role in the function of fetal and adult hematopoietic stem cell maintenance; however, the precise function of ATF4 in the bone marrow niche and the mechanism by which ATF4 regulates adult hematopoiesis remain largely unknown. Here, we employ four cell-type-specific mouse Cre lines to achieve conditional knockout of Atf4 in Cdh5+ endothelial cells, Prx1+ bone marrow stromal cells, Osx+ osteo-progenitor cells, and Mx1+ hematopoietic cells, and uncover the role of Atf4 in niche cells and hematopoiesis...
April 24, 2024: Blood
https://read.qxmd.com/read/38656885/description-of-the-characteristics-of-patients-with-diseases-associated-with-immunosuppression-and-cryptosporidium-spp-infection-seen-at-a-referral-children-s-hospital-in-argentina-2018-2023
#10
JOURNAL ARTICLE
Miguel Dumas Marucci, Sebastián Genero, Juan I Degiuseppe, Magali Pérez Garófalo, Juliana Perazzo
Cryptosporidium spp. is a diarrhea-causing protozoan. Immunocompromised patients may develop severe and persistent clinical forms. Here we describe the characteristics of patients with an underlying disease associated with immunosuppression (DAI) and Cryptosporidium spp. infection seen at a referral children's hospital in Argentina between 2018 and 2023. Demographic data, DAI, diarrhea characteristics, and co-infections were analyzed. A total of 30 patients with DAI and cryptosporidiosis were included. Most of them had undergone a solid organ transplant, had a hematologic neoplasm, or primary immunodeficiency...
April 25, 2024: Archivos Argentinos de Pediatría
https://read.qxmd.com/read/38656653/systematic-literature-review-on-the-incidence-of-herpes-zoster-in-populations-at-increased-risk-of-disease-in-the-eu-eea-switzerland-and-the-uk
#11
JOURNAL ARTICLE
Alen Marijam, Nikki Vroom, Amit Bhavsar, Inga Posiuniene, Nicolas Lecrenier, Hilde Vroling
INTRODUCTION: Older adults and patients with underlying conditions such as immunocompromised (IC) populations (e.g., due to medical conditions or immunosuppressive medication) are at increased risk for herpes zoster (HZ). The first HZ recombinant vaccine for IC patients was approved in 2020. Limited evidence exists to inform decision-makers on HZ incidence in high-risk patients in Europe. This systematic literature review (SLR) assessed HZ incidence across 14 high-risk populations in the European Union/European Economic Area, Switzerland, and the United Kingdom...
April 24, 2024: Infectious Diseases and Therapy
https://read.qxmd.com/read/38656630/safety-and-efficacy-of-multiple-dose-versus-single-dose-mibg-therapy-in-patients-with-refractory-pheochromocytoma-and-paraganglioma-a-single-center-retrospective-analysis
#12
JOURNAL ARTICLE
Naoto Wakabayashi, Shiro Watanabe, Takashige Abe, Junki Takenaka, Kenji Hirata, Rina Kimura, Keita Sakamoto, Nobuo Shinohara, Kohsuke Kudo
OBJECTIVE: To investigate the incidence of adverse events (AEs) following single and multiple administrations of I-131 metaiodobenzylguanidine (MIBG) therapy for inoperable pheochromocytomas and paragangliomas (PPGLs). METHODS: A single-center retrospective study was conducted on patients with inoperable PPGLs who underwent I-131 MIBG therapy between January 2000 and December 2020. A total of 28 patients with available electronic medical records were included. The treatment consisted of a single intravenous administration of 150 mCi (5...
April 24, 2024: Annals of Nuclear Medicine
https://read.qxmd.com/read/38656461/role-of-the-sting%C3%A2-pathway-in-myeloid-neoplasms-a-prospero-registered-systematic-review-of-principal-hurdles-of-sting%C3%A2-on-the-road-to-the-clinical-practice
#13
REVIEW
Leticia Rodrigues Sampaio, Ricardo Dyllan Barbosa Dias, João Vitor Caetano Goes, Renata Pinheiro Martins de Melo, Daniela de Paula Borges, Mayara Magna de Lima Melo, Roberta Taiane Germano de Oliveira, Howard Lopes Ribeiro-Júnior, Silvia Maria Meira Magalhães, Ronald Feitosa Pinheiro
Myeloid neoplasms are a group of bone marrow diseases distinguished by disruptions in the molecular pathways that regulate the balance between hematopoietic stem cell (HSC) self-renewal and the generation of specialized cells. Cytokines and chemokines, two important components of the inflammatory process, also influence hematological differentiation. In this scenario, immunological dysregulation plays a pivotal role in the pathogenesis of bone marrow neoplasms. The STING pathway recognizes DNA fragments in the cell cytoplasm and triggers an immune response by type I interferons...
April 24, 2024: Medical Oncology
https://read.qxmd.com/read/38656370/unrelated-umbilical-cord-blood-transplantation-with-low-dose-anti-thymocyte-globulin-for-children-with-severe-aplastic-anemia-a-case-series
#14
JOURNAL ARTICLE
Mengze Hu, Junhui Li, Rong Liu, Zhaoxia Zhang, Shunqiao Feng, Dixiao Zhong, Ruihong Tang, Litian Xuan
OBJECTIVE: This study aimed to investigate the prognosis of unrelated umbilical cord blood transplantation (UCBT) using low-dose anti-thymocyte globulin (ATG) in children diagnosed with severe aplastic anemia (SAA). METHODS: This retrospective case series study was conducted involving pediatric SAA patients treated at the Capital Institute of Pediatrics from January 2020 to February 2023. All patients underwent a reduced-intensity conditioning (RIC) regimen alongside low-dose ATG...
April 24, 2024: Annals of Hematology
https://read.qxmd.com/read/38656354/a-new-vision-of-the-efficacy-of-both-car-nk-and-car-t-cells-in-treating-cancers-and-autoimmune-diseases
#15
REVIEW
Salim Hussein Hassan, Mohammad Y Alshahrani, Raed Obaid Saleh, Bahira Abdulrazzaq Mohammed, Abhinav Kumar, Sami G Almalki, Adnan Taan Alkhafaji, Pallavi Ghildiyal, Ahmed Read Al-Tameemi, Ahmed Elawady
Chimeric Antigen Receptor (CAR) based therapies are becoming increasingly important in treating patients. CAR-T cells have been shown to be highly effective in the treatment of hematological malignancies. However, harmful therapeutic barriers have been identified, such as the potential for graft-versus-host disease (GVHD), neurotoxicity, and cytokine release syndrome (CRS). As a result, CAR NK-cell therapy is expected to be a new therapeutic option. NK cells act as cytotoxic lymphocytes, supporting the innate immune response against autoimmune diseases and cancer cells by precisely detecting and eliminating malignant cells...
April 24, 2024: Medical Oncology
https://read.qxmd.com/read/38656201/posaconazole-versus-voriconazole-as-antifungal-prophylaxis-for-invasive-fungal-diseases-in-patients-with-hematological-malignancies
#16
JOURNAL ARTICLE
Reem Almutairy, Mansoor Ahmed Khan, Alaa Shahbar, Mohammed Aseeri, Majed Alshamrani, Hassan Almarhabi, Doaa Naeem
INTRODUCTION: The incidence of invasive fungal diseases (IFDs) has risen in hematologic malignancy patients due to neutropenia. While posaconazole is recommended as the first-line antifungal prophylaxis in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients and voriconazole is an alternative, there is currently no direct comparison data available to assess their relative effectiveness. METHOD: We retrospectively reviewed eligible patient charts from January 2017 to February 2019 to identify breakthrough IFD rates, drug adverse event frequency, and drug acquisition cost in AML/MDS patients...
April 24, 2024: Journal of Oncology Pharmacy Practice
https://read.qxmd.com/read/38656143/reference-value-fibrin-monomer-in-healthy-children-a-cross-sectional-study
#17
JOURNAL ARTICLE
Ta Anh Tuan, Tran Dang Xoay, Tran Thi Kieu My, Nguyen Thi Duyen, Nguyen Thi Trang, Nguyen Tat Kien, Chu Thanh Son, Nguyen Van Thang, Thieu Quang Quan, Dau Viet Hung
The objective of this study is to determine the fibrin monomer reference intervals in healthy children. This cross-sectional study was conducted in the Hematology Department at Vietnam National Children's Hospital (April 2023 to March 2024). Children without prior history of clotting disorders or anticoagulants use hospitalized in preparation for orthopedic surgery or inguinal hernia surgery were enrolled in the study. The fibrin monomer test method was the quantitative fibrin monomer test on the STA-R system (Diagnostica Stago™, France)...
2024: Clinical and Applied Thrombosis/hemostasis
https://read.qxmd.com/read/38655905/short-term-biological-toxicity-prediction-of-177-lu-lutetium-oxodotreotide-an-original-retrospective-analysis
#18
JOURNAL ARTICLE
Julien Dubois, Guillaume Tosato, Philippe Garrigue, David Taieb, Benjamin Guillet, Vincent Nail
Introduction: [177 Lu]Lutetium (Lu)-oxodotreotide is a radiopharmaceutical drug used as peptide receptor radionuclide therapy (PRRT) for somatostatin receptor-expressing neuroendocrine neoplasms. It provides an additional effective alternative treatment for these rare cancers. Although well tolerated, its safety profile must continue to be characterized to support its use as a first-line treatment or for additional cycles. This study aims to evaluate factors associated with the occurrence of [177 Lu]Lu-oxodotreotide induced short-term toxicity...
April 24, 2024: Cancer Biotherapy & Radiopharmaceuticals
https://read.qxmd.com/read/38655854/fall-prevention-in-a-pediatric-unit-a-best-practice-implementation-project
#19
JOURNAL ARTICLE
Nydjia Lawrence, Robin Christian, Michelle Palokas, Linda Upchurch
INTRODUCTION: Inpatient falls account for 6% to 24% of pediatric safety incidents and can lead to increased length of hospital stay, increased cost of care, and decreased satisfaction with care. A review of a pediatric hematology, oncology, neurology, and rehabilitation unit in a hospital in the southern United States revealed an average of one to two falls monthly. OBJECTIVE: This project aimed to promote evidence-based practices (EBPs) regarding fall prevention in the pediatric unit...
April 25, 2024: JBI evidence implementation
https://read.qxmd.com/read/38655690/identification-of-a-novel-splice-variant-in-sec23b-gene-in-a-patient-with-concomitant-presence-of-congenital-dyserythropoietic-anemia-ii-and-gilbert-s-syndrome
#20
JOURNAL ARTICLE
Woori Jang, Dong Jun Ha, Chung Hyun Nahm, Jisun Park, Su Jin Kim, Ji-Eun Lee, Yeonsook Moon
BACKGROUND: Congenital dyserythropoietic anemia Ⅱ (CDA Ⅱ) is a rare inherited disorder of defective erythropoiesis caused by SEC23B gene mutation. CDA Ⅱ is often misdiagnosed as a more common type of clinically related anemia, or it remains undiagnosed due to phenotypic variability caused by the coexistence of inherited liver diseases, including Gilbert's syndrome (GS) and hereditary hemochromatosis. METHODS: We describe the case of a boy with genetically undetermined severe hemolytic anemia, hepatosplenomegaly, and gallstones whose diagnosis was achieved by targeted next generation sequencing...
December 2024: Hematology (Amsterdam, Netherlands)
keyword
keyword
1828
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.